Immunine

Human Coagulation Factor IX, the active ingredient in Immunine, is a coagulation factor presented as an injectable solution for intravenous use. It replaces deficient factor IX to treat patients with hemophilia B and acquired factor IX deficiency. GNH USA supplies Immunine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Immunine is used within the coagulation factor replacement therapy pathway to manage bleeding disorders. Hemophilia B: restores normal clotting and reduces bleeding episodes. Acquired factor IX deficiency: provides the missing factor to re‑establish hemostasis. Peri‑operative management in factor IX‑deficient patients: ensures adequate clot formation during surgery.

Immunine may cause adverse reactions following infusion.

Common Side Effects: - Infusion‑related reactions (fever, chills, flushing) - Headache - Nausea - Arthralgia - Mild hypertension - Transient increase in liver enzymes

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction - Development of neutralizing inhibitors (antibodies) to factor IX - Thromboembolic events (deep vein thrombosis, pulmonary embolism) - Severe hypertension or hypertensive crisis - Renal impairment or acute kidney injury - Disseminated intravascular coagulation (rare)

Before using Immunine, consider the following precautions. Monitor for inhibitor development: test for anti‑factor IX antibodies periodically. Assess allergy history: avoid in patients with known hypersensitivity to factor IX products. Use cautiously in cardiovascular disease: monitor blood pressure and signs of thrombosis. Avoid concurrent use with other pro‑coagulant agents unless medically indicated. Ensure dosing is individualized by a qualified haemophilia specialist. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Immunine may interact with other medicines that affect coagulation.

Major Interactions (Avoid): - Concomitant use of anticoagulants such as warfarin may diminish therapeutic effect and increase bleeding risk. - Simultaneous administration of activated prothrombin complex concentrates can raise the risk of thrombotic complications.

Moderate Interactions (Monitor Closely): - Aspirin or NSAIDs may exacerbate bleeding tendencies; monitor haemostasis. - Other clotting factor concentrates may alter dosing requirements; adjust under specialist guidance. - Immunosuppressive agents could influence inhibitor formation; observe antibody titres.